PDUFA Bill Moves To Senate Mark-Up, But Without Generic Biologics Language
This article was originally published in The Pink Sheet Daily
Executive Summary
April 18 session is planned in the HELP Committee as advocates for follow-on pathway continue to press their case.
You may also be interested in...
BIO Establishes Principles For Follow-on Biologics To Guide Lawmakers
In letters sent to legislators, BIO asks Congress to adopt the principles, emphasizing patient health and biotech innovation.
Drug Safety Bill From Sens. Kennedy And Enzi Faces Rival Version In The House
Reps. Waxman and Markey introduce legislation to give FDA stronger post-market enforcement authority, including higher fines than in a Senate version of the bill.
Generic Biologic Bill Needs Clinical Data Requirements, Sen. Hatch Says
At Senate hearing, co-author of ANDA legislation says that FDA should require clinical trials from sponsors seeking follow-on biologic approval.